Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oramorph is an opioid analgesic that acts within the central nervous system to manage pain across several clinical contexts. - Acute postoperative pain: provides rapid relief following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic pain: used when long‑term opioid therapy is indicated. - Traumatic injury pain: alleviates intense pain from major injuries. - Palliative care pain: contributes to comfort in end‑of‑life settings.

Adverse reactions to morphine may vary in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea and vomiting: stimulation of the chemoreceptor trigger zone. - Drowsiness or sedation: central nervous system depression. - Dry mouth: decreased salivary secretion. - Pruritus: histamine release causing itching. - Urinary retention: impaired bladder contractility.

Serious or Rare Side Effects: - Respiratory depression: reduced drive to breathe, potentially fatal. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or addiction: compulsive use despite harm. - Adrenal insufficiency: impaired cortisol production. - Anaphylaxis: rare severe allergic reaction. - Neurotoxicity: rare seizures or encephalopathy.

When prescribing Oramorph, clinicians should evaluate patient‑specific factors and monitor for adverse outcomes. - Assess renal and hepatic function: dose adjustments may be required in impairment. - Evaluate respiratory status: avoid use in patients with severe respiratory compromise. - Screen for substance‑use disorder: consider risk of dependence. - Use caution in the elderly: increased sensitivity to sedation and falls. - Avoid concurrent CNS depressants: heightened risk of respiratory depression. - Store at below 25°C: keep in the original container, protect from moisture and light.

Morphine interacts with several drug classes, requiring careful management to prevent enhanced toxicity or reduced analgesia.

Major Interactions (Avoid): - Benzodiazepines: synergistic respiratory depression. - Barbiturates: increased central nervous system depression. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergics: may worsen constipation. - Loop diuretics: can potentiate hypotension. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Antihistamines: additive sedation. - CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels.